Acellular Tissue Engineered Vessel

Brand names: Symvess · Active ingredient: Acellular Tissue Engineered Vessel

In short: SYMVESS™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

Forms & strengthsSYMVESS is an acellular tissue engineered vessel composed of organized extracellular matrix (ECM) proteins. SYMVESS is implanted using standard surgical techniques as a vascular construct to replace a patient’s damaged extremity artery after injury. …
LabelHumacyte Global, Inc.
Label updatedDec 17, 2025

What is Acellular Tissue Engineered Vessel used for?

SYMVESS™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

⚠ Boxed warning (FDA's strongest warning)

Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

Acellular Tissue Engineered Vessel dosage

SYMVESS is administered by surgical implantation to replace the injured extremity artery. The anatomical location in the extremity and length required should be determined by the surgeon implanting the graft based on the appropriate pre-operative clinical evaluation, vessel mapping and/or imaging, and intra-operative considerations. SYMVESS is provided as follows: 6 mm in internal diameter and 42 cm in length. Once removed from packaging, its usable length is approximately 40 cm.

Each package (i.e., box containing Tyvek®-sealed tray) contains one SYMVESS unit for administration to a single patient only.

SYMVESS may be trimmed to provide the length required for the artery replacement. SYMVESS can be trimmed to replace more than one injured extremity artery in the same patient.

Supplies:

The following supplies are not included in the carton, but may be needed for the handling of SYMVESS:

1) Sterile basin (as needed) – see Step 8 for details

2) Sheath tunneler (as needed) – see Section 2.3 and Step 3 for details

SYMVESS is to be handled in an appropriate surgical environment as follows:

Step 1: SYMVESS box contains a plastic thermoformed tray with a Tyvek® lid. Open the box and remove the plastic tray (Figure 1).

Figure 1: SYMVESS box and plastic tray

Step 2: After removing the tray from the box, check the FreezeAlert temperature indicator (Figure 2) attached to the side of the tray. If a check mark is displayed, SYMVESS has not been exposed to freezing temperatures and can be used. If an “X” is displayed, SYMVESS has been exposed to freezing temperatures and should NOT be used.

Figure 2: FreezeAlert Temperature indicator

Step 3: Two operators (one sterile operator and one non-sterile operator) are required to remove the sterile packaging bag containing SYMVESS from the plastic tray. Inspect the plastic tray to check for damage which can lead to loss in sterility of the SYMVESS. Do not open the tray for further use if the product is expired or has visible damage. If packaging is intact and within date of acceptable use, the non-sterile operator pulls back the Tyvek® lid by the corner tab to open the plastic tray containing the sterile packaging bag (Figure 3a and 3b). Take careful steps to avoid touching the sterile contents inside the tray (Figure 3c).

Figure 3a: Non-sterile operator pulls back the Tyvek® lid by the corner tab

Figure 3b: Non-sterile operator opens the plastic tray containing the sterile packaging bag

Figure 3c displays the components of SYMVESS within the plastic tray.

Figure 3c: SYMVESS with each component

Step 4: The non-sterile operator holds the bottom of the plastic tray with one hand and opens the Tyvek® lid with the other. …

How to take Acellular Tissue Engineered Vessel — instructions & advice from the label

Counsel the patient on the following:

Graft Rupture

Inform patients that bleeding can occur from the graft site and that subsequent intervention, explant, or additional procedures may be required after initial repair. Advise patients to seek urgent medical evaluation if they develop any bleeding from the surgical site, or have any signs or symptoms that would indicate failure of the graft such as worsening pain, loss of limb function or change in color of overlying skin. .

Anastomotic Failure

Inform patients that in certain situations, bleeding can occur at the graft anastomosis site and that subsequent intervention, explant, or additional procedures may be required to repair this. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin. .

Thrombosis

Inform patients that in certain situations, thrombosis can occur after SYMVESS implantation. At the surgeon's discretion, consider use of antiplatelet therapy following implantation of SYMVESS to reduce the risk of thrombosis. …

Warnings & precautions

Do not take this medicine if: DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries.

Vascular graft rupture has occurred in patients treated with SYMVESS . Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia.

Follow appropriate procedures for handling and administering SYMVESS .

Anastomotic failure has occurred in patients treated with SYMVESS . In clinical studies of SYMVESS, anastomotic failure occurred within the first 36 days post-implantation.

Monitor patients for signs of anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin.

Follow appropriate procedures for handling and administering SYMVESS .

Thrombosis has occurred in patients treated with SYMVESS . In clinical trials of SYMVESS, patients received antiplatelet therapy following implantation of SYMVESS to reduce the risk of thrombosis. The risk of thrombosis may increase in patients who discontinue antiplatelet therapy.

Anti-platelet therapy is recommended following treatment with SYMVESS.

SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or infectious agents. …

Acellular Tissue Engineered Vessel side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a product cannot be directly compared to adverse reaction rates in clinical trials of other products, and they may not reflect the rates observed in real-world clinical practice.

The safety data described in this section reflect exposure to SYMVESS in one single arm, open-label study in patients requiring vascular replacement or reconstruction for life or limb threatening vascular trauma, Study 1 (CLN-PRO-V005; NCT03005418). A total of 54 adults received extremity implantation of SYMVESS as a vascular conduit.

The patient population ranged in age from 18 to 72 years (mean age 33 years). Each patient received a SYMVESS implant ranging in length from 1 to 35 cm (mean length 10.1 cm). The most frequently occurring adverse reactions are shown in Table 1.

Adverse ReactionAdverse Reaction Frequency based on up to 3 years follow-up data [median 191 days (range 1-1134 days)] | Extremity Patients (%)Extremity patients are with arterial repair in upper or lower limbs

(n=54)

Vascular graft thrombosis | 15 (28%)

Pyrexia (fever) | 9 (17%)

Pain | 8 (15%)

Anastomotic stenosis | 5 (9%)

Vascular graft rupture or anastomotic failure | 4 (7%)

Vascular graft infection | 3 (6%)

Long term follow-up of up to 36 months in Study 1 is ongoing. …

About this medicine

SYMVESS is a sterile, acellular tissue engineered vessel composed of human extracellular matrix (ECM) proteins typically found in human blood vessels. SYMVESS is 6 mm in internal diameter and 42 cm in length (approximately 40 cm of usable length).

SYMVESS is manufactured using a tissue engineering process. Human vascular smooth muscle cells that are derived from human aortic tissue deemed suitable for transplant are banked, expanded, and seeded onto a tubular mesh scaffold. The cell-seeded scaffold is cultured in a biomimetic bioreactor system to generate an intermediate tubular construct containing vascular smooth muscle cells and the extracellular matrix the cells deposited. A final decellularization process removes the human cellular and genetic material while maintaining the extracellular matrix structure and mechanical and biological activity.

SYMVESS manufacture includes use of reagents derived from human and animal materials. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 15e9e29f-5aa6-4fc6-b0fe-a48cd1473418. Read the full official label on DailyMed.